Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) issued new guidelines on management of cardiovascular (CV) risk in primary prevention. 1 They developed a new CV risk calculator [new pooled cohort atherosclerotic CV disease (CVD) risk equation] targeting individuals between 40 and 75 years and based on four American population-based cohorts. 2,3 Statin treatment is recommended for individuals with an estimated 10-year risk of CVD ≥7.5%, including stroke. Conversely, the guidelines of the European Society of Cardiology (ESC) advocate the use of the SCORE equation for individuals aged between 40 and 65 years, and initiation of a statin treatment is recommended if the estimated 10-year risk of death from CVD is ≥5%. 4 Whether applying the ACC/AHA guidelines has similar public health consequences as applying the ESC guidelines is currently unknown. Hence, we used the data from a large, population-based study, to assess the countrywide population and economic impact of these new guidelines, supposing full adherence to treatment recommendations.
individuals (2.2-fold in men and 1.9 fold in women) relative to the SCORE function. The biggest differences were observed for age group 50-60 years, where the ACC/AHA guidelines led to a 30-fold increase in the number of high-risk individuals relative to the ESC guidelines. Full compliance with the ACC/AHA guidelines would also lead to an extra cost of treatment of 1.124 million CHF per day (410 million CHF, or 333.7 million E, per year).
We conclude that, relative to the ESC guidelines, the 2013 ACC/ AHA guidelines lead to a considerable increase in the number of highrisk individuals susceptible of receiving statin treatment. This increase is particularly strong in the age group 50-60 years. One likely explanation for this discrepancy may be due to differences in the prevalence of CV risk factors between the USA and Europe. 6, 7 Consequently, if fully implemented, the ACC/AHA guidelines might lead to a considerable increase in primary prevention costs of CVD. Further studies are needed to validate the new ACC/AHA risk equation and to assess the cost-effectiveness of the ACC/AHA guidelines in non-US countries. 
